Single-agent ibrutinib resulted in sustained efficacy and durable responses in treatment-naive or relapsed/refractory CLL or SLL, 5-year results show.
A preplanned analysis of ctDNA found that a subpopulation of mCRC patients with acquired anti-EGFR resistance were sensitive to treatment with Sym004.
Investigators have discovered that clofarabine and cladribine may be used as a targeted therapy in diseases where CD99 plays a critical role, including Ewing sarcoma and auto-immune disorders.
A new multianalyte test simultaneously evaluates levels of eight cancer proteins and the presence of cancer gene mutations from circulating DNA in the blood, offering clinicians and patients a potentially affordable way of detecting cancer at an earlier stage.
Researchers have made a discovery linking chromosomal instability to cancer metastasis through chronic inflammation, a first in identifying a widespread genomic driver of metastasis.
ImmunoMap, which can examine T-cell receptor repertoire relatedness, may help predict clinical outcome for patients with cancer and could be a new tool for designing vaccines and immunotherapies.
The combination therapy increased the attraction of immune cells to fight non-small cell lung cancer and also boosted the response to immune checkpoint inhibitors.
MMG49 has been identified as a monoclonal antibody that can be targeted using CAR T-cell therapy for patients with multiple myeloma.
A recent study showed that molecular tumor boards coupled with cognitive computing with IBM's Watson could improve patient care by providing a rapid, comprehensive approach for data analysis.
Data presented at the ASTRO annual meeting demonstrate a benefit of radiation plus immunotherapy for patients with advanced disease, including stage IV NSCLC.